Evommune (EVMN) Q3 2025 earnings summary

Executive summary

• Completed IPO in November 2025, raising $172.5 million in gross proceeds, with net proceeds of $160.4 million, strengthening financial position for upcoming milestones.

• Focused on developing therapies for chronic inflammatory diseases, with lead candidates EVO756 and EVO301 in Phase 2 trials for multiple indications including CSU, AD, and UC.

• Anticipates three Phase 2 data readouts in 2026 for EVO756 and EVO301 targeting atopic dermatitis and chronic spontaneous urticaria.

• Pipeline progress includes positive Phase 2 data for EVO756 in chronic inducible urticaria and ongoing expansion into additional indications.

• Accumulated deficit reached $192.8 million as of September 30, 2025, with continued net losses expected as R&D and operational expenses increase.

Financial highlights

• License revenue was $13.0 million for the nine months ended September 30, 2025, up from $7.0 million in the prior year period, driven by milestone payments from Maruho.

• Revenue for Q3 2025 was $10.0 million, compared to zero in Q3 2024, driven by a licensing collaboration.

• Net loss for the nine months ended September 30, 2025 was $40.6 million, compared to $46.1 million in the same period in 2024.

• Research and development expenses increased to $53.6 million for the nine months ended September 30, 2025, primarily due to higher clinical trial and discovery research costs.

• Cash, cash equivalents, and short-term investments totaled $76.1 million as of September 30, 2025, prior to IPO proceeds.

Outlook and guidance

• Expects top-line Phase 2b data for EVO756 in CSU in the first half of 2026 and in AD in the second half of 2026.

• Phase 2a data for EVO301 in AD anticipated in the first half of 2026.

• Current cash, cash equivalents, short-term investments, and IPO proceeds are expected to fund operations into the second half of 2028.

• Anticipates continued increases in R&D and G&A expenses as clinical programs advance and company scales operations.

• No product revenue expected for several years; future funding needs will depend on clinical progress and milestone achievements.